OncLive Staff

Articles by OncLive Staff

FDA Grants Selinexor Priority Review for Multiple Myeloma

October 6th 2018

The FDA has granted a priority review to a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma.

IDO Inhibitors Emerging as New Players on Checkpoint Blockade Scene

ByOncLive Staff

August 15th 2017

As researchers continue to explore immune checkpoints as targets for anticancer therapies, the IDO pathway has emerged as the leading contender to yield the next batch of new drugs in the field.

OncLive Staff

Articles by OncLive Staff

FDA Grants Selinexor Priority Review for Multiple Myeloma

IDO Inhibitors Emerging as New Players on Checkpoint Blockade Scene

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

China's NMPA Approves Pirtobrutinib Across CLL

FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer

Calculating the Real Cost of False Positive Findings in Cancer Screening